My research is focused on how the endothelin system is disrupted in the brain in Alzheimer’s disease. There are differences in the levels of ECE-2 and ECE-1, the activity of ECE-1 and the level of ET-1 in the brain in Alzheimer’s disease compared to controls, and I am interested in why this is, and what effect this may have in patients. There appears to be a link between disruption of the endothelin system and the reduction of cerebral blood flow in Alzheimer’s disease, and part of my research is to investigate the mechanism of this. A large part of my current work is to investigate whether disruption in the endothelin system plays a role in the recently recognised interrelationship between hypertension, ischaemic brain damage, and Alzheimer’s disease, particularly the potential involvement of Aβ on ECE-mediated regulation of cerebral blood flow. I am currently looking in more detail at the therapeutic potential of these findings for a new treatment of Alzheimer’s disease.